Phreesia, Inc. (NYSE:PHR) executive David Linetsky, who serves as the Senior Vice President of Life Sciences, has recently sold a portion of his company stock, according to the latest filings with the Securities and Exchange Commission. The transactions, which took place on June 18 and June 20, 2024, involved a total sale of $2,089 worth of shares at prices ranging from $19.1971 to $19.7322.
The SEC filing revealed that on June 18, Linetsky sold 41 shares at a price of $19.1971 per share, followed by a disposal of 66 shares at $19.7322 each on June 20. These sales were conducted under a mandatory sell-to-cover policy to satisfy tax withholding obligations related to the settlement of restricted stock units (RSUs).
Following these transactions, the filing indicated that Linetsky's directly owned stake in Phreesia, Inc. has been adjusted. However, the specific details of his remaining holdings were not disclosed in the summary of the filing.
Investors often monitor insider transactions as they can provide insights into executives' perspectives on their company's stock value. While these sales are a routine part of compensation and tax planning for corporate insiders, they are nonetheless of interest to the investment community.
Phreesia, Inc., headquartered in Wilmington, Delaware, specializes in business services within the healthcare sector, offering a platform for patient intake management and other services designed to improve the healthcare experience for both patients and providers.
The company's stock, traded under the ticker symbol NYSE:PHR, may experience investor scrutiny following these insider transactions. As always, investors are advised to consider the broader context of the market, the company's performance, and other relevant factors when assessing the potential impact of insider stock sales on their investment decisions.
In other recent news, Phreesia Inc . reported a significant 21% increase in revenue, reaching $101.2 million, and a positive adjusted EBITDA of $4.1 million, marking its first positive EBITDA quarter in three years. This positive financial development led to an upward revision of the company's FY25 EBITDA outlook by $7.5 million at the midpoint. However, the company revised its revenue guidance downward by $8 million due to the hastened conclusion of a clearinghouse partnership.
Recent analyst notes reveal DA Davidson reaffirmed its Buy rating on Phreesia stock, highlighting the company's growth potential and valuation, while JPMorgan (NYSE:JPM) adjusted its price target to $27, maintaining an 'Overweight' rating. RBC (TSX:RY) Capital held steady with a 'Sector Perform' rating and a price target of $23, and Needham reiterated their 'Buy' rating with a $29 price target.
The reaffirmation of these ratings and price targets come at a time when the healthcare technology industry is increasingly in focus, with investors closely monitoring the performance of companies like Phreesia. These are among the recent developments shaping the company's financial and operational trajectory.
InvestingPro Insights
As Phreesia, Inc. (NYSE:PHR) navigates the healthcare business services market, recent insider trading activity has caught the eye of investors. To provide a more comprehensive view of the company's financial health and market performance, we turn to InvestingPro Insights for real-time data and expert analysis.
The company's market capitalization stands at $1.16 billion, indicating a sizable presence in its industry segment. Despite a notable revenue growth of nearly 24% over the last twelve months as of Q1 2025, Phreesia has not been profitable during this period, with a reported operating income margin of -30.32%. This aligns with the InvestingPro Tips that suggest analysts do not anticipate the company will be profitable this year.
Additionally, Phreesia's stock has experienced a downturn over the past month, with a 15.28% decrease in price total return. This short-term performance may be of particular interest to investors following the recent insider sales. The company's P/E ratio, at -9.37, further reflects the challenges it faces in achieving profitability. Moreover, with a PEG ratio of -0.33, investors may need to adjust their growth expectations in relation to the company's earnings.
For those looking for more in-depth analysis, InvestingPro Tips indicate that seven analysts have revised their earnings upwards for the upcoming period, which could signal a potential shift in the company's financial trajectory. However, it's important to note that Phreesia does not pay dividends, which might influence the investment strategy of income-focused shareholders.
For additional insights and tips, including 5 more InvestingPro Tips for Phreesia, Inc., investors can visit https://www.investing.com/pro/PHR. Those interested in a yearly or biyearly Pro and Pro+ subscription can use the coupon code PRONEWS24 to receive an additional 10% off, providing access to valuable investment tools and data to inform their market decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.